DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1, 4-5, 7, 11, and 14-16 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ikeda et al. (WO 2013/175747) (“Ikeda”) (English translation from PatentScope used for citation).
With regard to claim 1, Ikeda discloses an organic light-emitting device comprising: a first electrode (“ITO transparent electrode”, par [0072]); a second electrode (“80nm-thick metal Al were sequentially laminated to form the cathode,”, par [0072]) facing the first electrode (“ITO transparent electrode”, par [0072]); a first layer (“compound (HT-1)”, par [0072]) between the first electrode (“transparent electrode”, par [0072]) and the second electrode (“cathode”, par [0072]), the first layer (“compound (HT-1)”, par [0072]) comprising a first compound (“compound (HT-1)”, par [0072]); a second layer (“compound (BD)”, par [0072]) between the first layer (“compound (HT-1)”, par [0072]) and the second electrode (“cathode”, par [0072]), the second layer (“compound (BD)”, par [0072]) comprising a second compound (“compound (BD)”, par [0072]); and a third layer (“compound (ET-1)”, par [0072]) between the second layer (“compound (BD)”, par [0072]) and the second electrode (“cathode”, par [0072]), the third layer (“compound (ET-1)”, par [0072]) comprising a third compound (“compound (ET-1)”, par [0072]); wherein the first compound (“compound (HT-1)”, par [0072]) does not comprise a nitrogen-containing heterocyclic group comprising *=N-*' as a ring forming moiety, wherein the first compound (“compound (HT-1)”, par [0072]) and the second compound (“compound (BD)”, par [0072]) each independently comprise at least one group selected from groups represented by Formulae A to C: (“compound (HT-1)”, “compound (BD)”, par [0072]); and wherein the third compound (“compound (ET-1)”, par [0072]) selected from compounds represented by Formulae 2D-1, 2D-2, 3-1 and 3-2: Formula 2D-1 (“compound (ET-1)”, par [0072]).
With regard to claim 4, Ikeda disclose wherein ring A1 (“compound (HT-1)”, par [0072]), ring A11, and ring A12 are each independently selected from a benzene group (“compound (HT-1)”, par [0072]), a naphthalene group, a fluorene group, a benzofluorene group, a pyridine group, a pyrimidine group, a carbazole group, a benzocarbazole group, and a dibenzothiophene group.
With regard to claim 5, Ikeda discloses wherein, in Formulae A to C (“compound (HT-1)”, par [0072]).
With regard to claim 7, Ikeda discloses wherein the first compound (“compound (HT-1)”, par [0072]) is selected from compounds represented by Formulae 1-1 (“compound (HT-1)”, par [0072]) to 1-3, and the second compound (“compound (BD)”, par [0072]) is selected from compounds represented by Formulae 2H-1, 2D-1 (“compound (BD)”, par [0072]), and 2D-2, and the third compound (“compound (ET-1)”, par [0072]) comprises a nitrogen-containing heterocyclic group comprising *=N-*' as a ring forming moiety, and in Formula 3-1, at least one selected from Ar41 to Ar43 is a group selected from groups represented by Formulae A to C, in Formula 3-2, one selected from Ar41 and Ar42 is a group selected from groups represented by Formulae A to C, and the other one selected from Ar41 and Ar42 is a nitrogen-containing heterocyclic group comprising *=N-*' as a ring-forming moiety.
With regard to claim 11, Ikeda discloses wherein the first compound (“compound (HT-1)”, par [0072]) is selected from compounds represented by Formulae 1-1 (“compound (HT-1)”, par [0072]), 1-2, and 1-3, the second compound (“compound (BD)”, par [0072]) is selected from compounds represented by Formulae 2D-1 (“compound (BD)”, par [0072]) and 2D-2, and the third compound (“compound (ET-1)”, par [0072]) is selected from compounds represented by Formulae 3-1 and 3-2 (“compound (ET-1)”, par [0072]).
With regard to claim 14, Ikeda discloses wherein the first compound (“compound (HT-1)”, par [0072]) and the second compound (“compound (BD)”, par [0072]) are each independently selected from compounds represented by Formulae 1-1 (“compound (HT-1)”, par [0072]), 1-2, and 1-3, the first compound (“compound (HT-1)”, par [0072]) being different from the second compound (“compound (BD)”, par [0072]), and the third compound (“compound (ET-1)”, par [0072]) is selected from compounds represented by Formulae 2D-1, 2D-2, 3-1, and 3-2 (“compound (ET-1)”, par [0072]).
With regard to claim 15, Ikeda discloses wherein the first compound (“compound (HT-1)”, par [0072]) and the second compound (“compound (BD)”, par [0072]) are each independently selected from compounds represented by Formulae 1-1(1) to 1-1(4) (“compound (HT-1)”, par [0072]), 1-2(1) (“compound (BD)”, par [0072]), and 1-3(1), and the third compound (“compound (ET-1)”, par [0072]) is selected from compounds represented by Formulae 2D-1(1) to 2D-1(4), 2D-2(1), 2D-2(2), 3-1(1), 3-1(2), and 3-2(1) (“compound (ET-1)”, par [0072]).
With regard to claim 16, Ikeda discloses wherein the first compound (“compound (HT-1)”, par [0072]) and the second compound (“compound (BD)”, par [0072]) are each independently selected from compounds represented by Formulae 1-1 (“compound (HT-1)”, par [0072]), 1-2 (“compound (BD)”, par [0072]), and 1-3, the first compound being different from the second compound, and the third compound (“compound (ET-1)”, par [0072]) is selected from compounds represented by Formulae 3-1 and 3-2 (“compound (ET-1)”, par [0072]).
Allowable Subject Matter
Claims 2-3, 6, 8-10, 12-13, and 17-20 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to BENJAMIN T LIU whose telephone number is (571)272-6009. The examiner can normally be reached Monday-Friday 11:00am-7:30pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Yara J Green can be reached at 571 270-3035. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/BENJAMIN TZU-HUNG LIU/Primary Examiner, Art Unit 2893
Prosecution Insights